Skip Navigation



European Heart Journal Advance Access published online on January 9, 2009
European Heart Journal, doi:10.1093/eurheartj/ehn565
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/2/131    most recent
ehn565v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gresele, P.
Right arrow Articles by Migliacci, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gresele, P.
Right arrow Articles by Migliacci, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

The peripheral arterial disease subgroup in the CHARISMA trial: does it tell us anything new?

Paolo Gresele1,* and Rino Migliacci2

1 Division of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia, Perugia, Italy
2 Division of Internal Medicine, Ospedale della Valdichiana ‘S. Margherita’, USL 8, Arezzo, Italy

* Corresponding author. Tel: +39 0755783989, Fax: +39 0755716083, Email: grespa@unipg.it

This editorial refers to ‘Patients with peripheral arterial disease in the CHARISMA trial’{dagger} by P.P. Cacoub et al. on page 192

The first 10% of the full text of this article appears below.

Peripheral arterial disease (PAD) is recognized as a serious cardiovascular disorder, in both epidemiological and prognostic terms. PAD is estimated to affect >27 million patients in Europe and the USA alone, and its prevalence is expected to increase further because it is typically associated with type II diabetes mellitus and with advanced age, conditions that will both steadily increase in the next decades.1 PAD patients are at markedly increased risk of major cardiovascular events; in particular, PAD is associated with a cardiovascular risk similar to that of patients with a previous myocardial infarction (MI) and with a life expectancy comparable with that of patients with some of the most common tumours.1,2 Patients with a previous MI or stroke who also have asymptomatic PAD have a significantly worse cardiovascular prognosis,3 and the combined presence of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Patients with peripheral arterial disease in the CHARISMA trial
Patrice P. Cacoub, Deepak L. Bhatt, P.Gabriel Steg, Eric J. Topol, Mark A. Creager, and for the CHARISMA Investigators
EHJ 2009 30: 192-201. [Abstract] [Full Text]